GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Shiller PE Ratio

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Shiller PE Ratio : (As of May. 11, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Momenta Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Momenta Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Shiller PE Ratio Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Momenta Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Shiller PE Ratio falls into.



Momenta Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Momenta Pharmaceuticals's E10 for the quarter that ended in Jun. 2020 is calculated as:

For example, Momenta Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2020 (Change)*Current CPI (Jun. 2020)
=-0.48/108.7673*108.7673
=-0.480

Current CPI (Jun. 2020) = 108.7673.

Momenta Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201009 0.700 92.162 0.826
201012 0.790 92.474 0.929
201103 1.130 94.283 1.304
201106 1.260 95.235 1.439
201109 1.180 95.727 1.341
201112 -0.030 95.213 -0.034
201203 -0.100 96.783 -0.112
201206 -0.200 96.819 -0.225
201209 -0.510 97.633 -0.568
201212 -0.350 96.871 -0.393
201303 -0.480 98.209 -0.532
201306 -0.570 98.518 -0.629
201309 -0.500 98.790 -0.550
201312 -0.590 98.326 -0.653
201403 -0.530 99.695 -0.578
201406 -0.510 100.560 -0.552
201409 -0.560 100.428 -0.607
201412 -0.310 99.070 -0.340
201503 -0.400 99.621 -0.437
201506 -0.040 100.684 -0.043
201509 -0.442 100.392 -0.479
201512 -0.430 99.792 -0.469
201603 -0.350 100.470 -0.379
201606 -0.310 101.688 -0.332
201609 -0.260 101.861 -0.278
201612 0.600 101.863 0.641
201703 -0.460 102.862 -0.486
201706 -0.500 103.349 -0.526
201709 -0.440 104.136 -0.460
201712 0.180 104.011 0.188
201803 -0.630 105.290 -0.651
201806 -0.910 106.317 -0.931
201809 -0.650 106.507 -0.664
201812 -0.100 105.998 -0.103
201903 -0.460 107.251 -0.467
201906 -1.160 108.070 -1.167
201909 -0.450 108.329 -0.452
201912 -0.850 108.420 -0.853
202003 -0.340 108.902 -0.340
202006 -0.480 108.767 -0.480

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Momenta Pharmaceuticals  (NAS:MNTA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Momenta Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Headlines